CSF2 and neoplasm: The third patient in this series with a locally aggressive clival chondroid chordoma was treated with MVX-ONCO-1 through an ongoing clinical trial (ClinicalTrials.gov (accessed on 2 March 2021) Identifier: NCT02193503): a personalized anti-tumor vaccine consisting of irradiated individual tumor cells, surrounded by a capsule of allogeneic, genetically modified cells that secrete GM-CSF to promote antigen-presenting cells to tumor neoantigens [78,79,80].